ADR Biomedical Holdings (TSE:3750) EBIT: 円-379.37 Mil (TTM As of Mar. 2026)


TSE:3750 ADR Biomedical Holdings Inc TSE:3750
30 GF Score
Price 円808.00
GF Value 円40.40
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is ADR Biomedical Holdings EBIT?

ADR Biomedical Holdings TSE:3750 +0.37% 30 EBIT is 円-379.37 Mil as of Mar. 2026. GuruFocus rates TSE:3750 with a GF Score™ of 30/100 and a GF Value™ of 円40.40 (Significantly Overvalued). The stock has 9 warning signs investors should review.

ADR Biomedical Holdings's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was 円-261.46 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was 円-379.37 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ADR Biomedical Holdings's annualized ROC % for the quarter that ended in Mar. 2026 was -694.16%. ADR Biomedical Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -683.83%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ADR Biomedical Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -5.35%.

ADR Biomedical Holdings  (TSE:3750) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ADR Biomedical Holdings's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-1147.182 * ( 1 - 0% )/( (253.02 + 77.502)/ 2 )
=-1147.182/165.261
=-694.16 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=603.894 - 60.662 - ( 290.212 - max(0, 196.997 - 574.213+290.212))
=253.02

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=368.058 - 166.768 - ( 125.901 - max(0, 226.721 - 350.509+125.901))
=77.502

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

ADR Biomedical Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-522.912/( ( (15.932 + max(137.004, 0)) + (0 + max(-142.806, 0)) )/ 2 )
=-522.912/( ( 152.936 + 0 )/ 2 )
=-522.912/76.468
=-683.83 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.576 + 62.643 + 215.782) - (60.662 + 0 + 86.335)
=137.004

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(8.188 + 66.41 + 9.317) - (166.768 + 0 + 59.953)
=-142.806

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ADR Biomedical Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-379.37/7088.003
=-5.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADR Biomedical Holdings EBIT Related Terms

ADR Biomedical Holdings EBIT Historical Data

* Premium members only.

The historical data trend for ADR Biomedical Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADR Biomedical Holdings EBIT Chart

ADR Biomedical Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.86 -1,036.84 -857.40 -2,070.77 -379.37

ADR Biomedical Holdings Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -517.43 -394.30 -1,676.47 -117.91 -261.46

TSE:3750 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, ADR Biomedical Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ADR Biomedical Holdings EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ADR Biomedical Holdings's EV-to-EBIT falls into.


TSE:3750
30GF Score
ADR Biomedical Holdings Inc TSE:3750
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADR Biomedical Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円-379.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円-379.37 Mil mean?
ADR Biomedical Holdings (TSE:3750) has a EBIT of 円-379.37 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ADR Biomedical Holdings.
Is ADR Biomedical Holdings' EBIT too high?
ADR Biomedical Holdings' current EBIT is 円-379.37 Mil. Overall, ADR Biomedical Holdings has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' EBIT compare to VRTX and REGN?
ADR Biomedical Holdings' EBIT of 円-379.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ADR Biomedical Holdings. ADR Biomedical Holdings's current EBIT is 円-379.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円40.40, compared to a current price of 円808.00 — trading 1900% above its estimated fair value. The current EBIT is 円-379.37 Mil. ADR Biomedical Holdings' overall GF Score™ is 30/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current EBIT is 円-379.37 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?

Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued. The current stock price of 円808.00 is trading 1900% above its estimated GF Value™ of 円40.40. GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.

Key valuation signals for TSE:3750:

  • EBIT: 円-379.37 Mil
  • GF Value™: 円40.40 vs. price of 円808.00 (1900% above fair value)
  • GF Score™: 30/100 with 9 warning signs

No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADR Biomedical Holdings Business Description

Address 1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
30GF Score

Get the complete analysis for TSE:3750

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円808.00
Price
円40.40
GF Value